 Rich Picks Daily is an online community for traders to exchange smart, straightforward and profitable investment ideas. Join us today at richpicksdaily.com, subscribe to us on YouTube to learn useful stock trading secrets and discover the next ten-banker. Hey, how are you guys doing? This is Rich from Rich to be Live and I have some more breaking news to bring to you today. Pharmathera announced a submission of IND application with the FDA for phase two clinical trial evaluating ketamine in the treatment of Parkinson's disease. Wow, big news for Pharmathera. And if you want to take a look at Pharmathera, this is them on Twitter, PHRM in Canada, PHRRF in America. You can hit the bell for notifications. I just did. So you could say only a few followers here. So you could be one of the first and we love to bring you information first and use first. This is their website, pharmathera.com, delivering psychedelic pharmaceuticals better. Now remember psychedelics have not been hot. They've actually been under a lot of selling pressure. Please do your due diligence. Please do your research before you invest in anything that we talk about here in Rich TV Live. Rich TV Live is strictly for information and education purposes. Small caps have been selling off. Psychedelics have been selling off under a lot of selling pressure, but we need to be aware of the news as it happens. And that's what we do here at Rich TV Live. We bring in the winners and we bring them to you first. And typically when stocks are down, that's the best time to buy. So I want to break this news down for you. I want to make sure you understand it. I want to make sure you guys know what it is because this could be huge in the future and this news is now starting to trend. This is their website. You can connect with them. And this is the company. You can do research, everything on their website here, guys. So everything is here on the website for you to review. And let's get into the news. So this is the big news. Pharma Thayer Holdings Limited, a specialty psychedelic pharmaceutical company that announced it submitted an investigational new drug, an IND application with the U.S. Food and Drug Administration, otherwise known as the FDA for the initial and initiation of a phase two clinical trial to evaluate the safety, efficacy, and pharma coccinetics of low dose ketamine in the treatment of levodopa-induced dekinesia in patients with Parkinson's disease. Huge, huge, huge issue with Parkinson's disease on a global scale. And this could be, could be, hopefully, a solution. The submission of our IND application with the FDA is in porn milestone as it provides us with a solid foundation to advance our ambition in commercializing ketamine and unlocking its therapeutic potential through novel uses, formulations, and delivery methods in a treatment of neurodegenerative diseases, Parkinson's disease and Lou Gehrig's disease, two terrible diseases, mental illness, example, depression and PTSD and chronic pain, said Fabio Cianelli, CEO of Pharma Thayer, who we've had on our show. Ketamine is an FDA-approved and methanol desparate, an MDA, receptor modeling, modulating drug that is widely used as an anesthetic agent either alone or in combination with other anesthetic agents, Smith et al in 1987, Pacheco et al 2014. The possible therapeutic effect of low dose ketamine on lid was noticed in a retrospective analysis of PD patients who received ketamine for pain relief. During this analysis, it was observed that the patients experienced an improvement in LID lasting several weeks beyond treatment. Sherman et al 2016, these are some examples of patients and treatments that have done in the past. These results were corroborated in a test of low dose ketamine in a rodent lid model. And this possible effect has also been examined in a controlled study, for example, in Bartlett 2016. Ketamine may also have additional benefits in the treatment of pain, niesters 2014, and depression for patient named Diamond in 2014 and Murrow in 2013, which are frequent comorabidites of Parkinson's disease. The clinical trial is titled a multicenter phase LLA randomized double blind prospective active placebo controlled trial of subanesthetic ketamine to treat levodoba induced dyskensia in subjects with Parkinson's disease is anticipated that up to eight clinical sites in the US will randomize a total of up to 36 subjects to the investigational product ketamine or active controlled mitazolum. The primary endpoint of the study is the change in the unified dyskensia rating scale total score from the baseline to week eight secondary endpoints of the study include the change in total objective scores of the baseline to week eight secondary endpoints of the study include the change in total objective scores of the UDRS total daily OFF times as assessed by subject completed 24 hour diaries and change in the UPDRS total and some scores of motor and dyskensia from baseline to week eight because lid can markedly affect a Parkinson's patients every day activities, a reduction in lid can improve the patient's quality of life. Assuming the phase two clinical trial is positive, the company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a pivotal phase three clinical study under the 505 B2 regulatory pathway. However, there can be no assurance that the FDA will support any potential request for the expedited path to approval or further development. Parkinson's disease is terrible, obviously, and you guys should follow Pharma there on LinkedIn. If you want to learn more about them, follow them on Twitter. If you want to get all their news and updates and go to their website, you know, you can get their investor information, follow their news, contact the company, get all the research you need to know, can take a look at their pipeline, take a look at everything right here on their website, guys. Now, one thing I want you to realize, especially with pharmaceuticals and psychedelics is it takes time. FDA approval takes time. So many people are investing in psychedelics and they don't have the patients to wait. Well, psychedelics are literally years away from FDA approval. So we're getting in early, I'm getting in early and I'm holding because I want front row seat to the rocket. But a lot of investors don't have that patience. So what you're seeing is a lot of small caps that are in the psychedelic space, people are buying them and they're selling now because they're not getting returns immediately. But if you're looking long term for a winner, this could be it. I mean Parkinson's is a major problem. And these guys are looking for a cure. That's huge. Parkinson's disease is a debilitating disorder that affects over one million people in the United States and more than seven million people worldwide. There's currently no cure for Parkinson's disease. There it is. This could be huge. This could be game changing, but it's not going to happen overnight. It's a long term play. It's going to take time. It's going to take testing. It's going to take FDA approval. So you have to understand that this is a long term trade when you're getting into these deals. This is not an instant day trade, an instant buy today, get a return tomorrow. This is more of a long term play. And remember Rich TV Live is strictly for education and information purposes. We do bring you the winners. We bring them to you first. And if you look at our track record, typically we bring you companies and months, sometimes years later, they absolutely explode because we bring them to you first. There's currently no cure for Parkinson's disease, although the ideology of PD is not fully understood. It is thought to result from loss of pigmented, depominergic neurons in the substantia nigra, and their stratole projections leading to dopamine deficiency in the stratum, scarpaea, and Jenner in 2011, and ultimately affects the cortico strytal system that controls movement. As a progressive neuro genetic disorder of the central nervous system that primarily affects the motor nerve system, symptoms of Parkinson's disease may emerge slowly and include tremors, rigidity, brady kinesia, and posterior instability. Paulson and Stern in 2004. Once again, other testing on other patients. Also patients may experience non-motor symptoms such as autonomic dysfunction and so many others or orthostatic hypertension, hypotension, constipation, bladder dysfunction, psychiatric depression, cognitive and sensory symptoms, pain. This was also used on all in all in 2009. These non-motor symptoms become more common as the disease progresses. Treatments including levodopa and dopamine agonists, which restore the dopamine deficits in the brain have been employed for almost 50 years. However, with continued treatment using levodopa, dose limiting motor side effects often emerge. These include the emergence of abnormal involuntary movements termed levodopa induced dyskinesia, which can be identified in about 50 percent of patients within five years after initiation of levodopa treatment and in almost all patients within 10 years post-treatment initiation. These side effects often limit further dose increases in dopaminergic therapy about pharma care holdings, pharma care holdings, PHRM in Canada. PHRF in America is a specialty psychedelic pharmaceutical company focused on the research development and commercialization of ketamine and novel micro needle patches for delivering psychedelics to treat neuro psychiatric neurodegenerative and pain disorders. So like I said earlier, guys, these psychedelics are years away, but if you want to get in early and you're looking for a long term winner and you want to get in early and get a front row seat tour rocket, and I've said this since day one, you got to get in and put it aside and just down the road. Eventually these types of plays can absolutely explode. You can see pharma third been trading between 20 and 30 cents kind of around 25 cents in Canada right now. If this does help Parkinson's disease, I don't see any reason why in the future this could eventually be a $1 stock. I can't guarantee it, but I think there's the chance and the beauty of Rich TV Live is we can sit here and we can debate it and talk about it and analyze it. It's an early stage company. It's under a dollar. It's a penny stock for a reason, guys. They don't got tons of money in the bank yet. They're not ready yet to explode. But if you want to get in early, this could be an early stage rocket. Once again, the big news. Pharma Thayer announced a submission of IND application with the FDA, the Food and Drug Administration, for phase two clinical trial evaluating ketamine in the treatment of Parkinson's disease. This could be absolutely huge. It's not going to happen overnight, but for those that are patient and are willing to look for a small cap company that could grow to something bigger one day, this could be it. What do you guys think? PHRM in Canada, PHRF in America? Comment down below, share the video everywhere, and subscribe if you're alive. If you're not winning, you're not watching. We're bringing the winners. We don't bring them to you fifth. We don't bring them to you tenth. We don't bring them to you fiftieth. We bring them to you first before anybody else knows. We find deals under rocks. We do the due diligence. We do the research. We read the news. We bring the news. You're a boy rich. You wish to be live and doing this in 2017. Better than anyone else on the planet. And I'm old. Peace.